期刊
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
卷 38, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s13046-019-1513-4
关键词
Colorectal Cancer; MKK3; p38 MAPK signalling; p38 delta MAPK; Chemotherapy; Target therapy; Combined treatments
类别
资金
- AIRC [18449]
- Alice triangi Pezcoller-Foundation fellowship
- Italian Ministry of Health
MKK3 is a member of the dual specificity kinase group specific upstream activator of p38 MAPK proteins. We originally identified MKK3 as mutant p53 (mutp53) gain-of-function (GOF) upregulated target gene in different tumor models. To deeply investigate the MKK3 functions in cancer, taking advantage of a panel of authenticated colorectal cancer (CRC) lines and primary colonocytes, we found that MKK3 activates specifically p38delta MAPK protein, which signaling is further triggered by 5-fluorouracil (5-FU) treatments, a largely adopted chemotherapeutic drug in CRC clinical practice. The overall achieved results proposed the MKK3/p38delta MAPK as relevant molecular axis involved in abrogating efficacy to 5-FU treatments in CRC. This commentary will provide an overall discussion of the results that have been achieved contextualizing them in the overview of the knowledge in the p38 MAPK field in cancer disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据